Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study

BMC Medical Genetics

Volumn 12, Issue , 2011, Pages

  Henderson, Samuel T ^a   Poirier, Judes ^b  

^a Accera Inc   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Apoe; Cognition; Ide; Il1b; Insulin; Ketone bodies; Memory

Indexed keywords

3 HYDROXYBUTYRIC ACID; AC 1202; APOLIPOPROTEIN E4; CAPRYLIC TRIGLYCERIDE; INSULINASE; INTERLEUKIN 1BETA; MEDIUM CHAIN TRIACYLGLYCEROL; UNCLASSIFIED DRUG; APOLIPOPROTEIN E3; KETONE BODY;

ALZHEIMER DISEASE; ARTICLE; COGNITION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; ENZYME BLOOD LEVEL; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HUMAN; KETOACIDOSIS; KETOGENESIS; MAJOR CLINICAL STUDY; MUSCLE CRAMP; NAUSEA; OUTCOME ASSESSMENT; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; FEMALE; GENETIC POLYMORPHISM; GENETICS; HOSPITALIZATION; MALE; MULTICENTER STUDY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULYSIN; INTERLEUKIN-1BETA; KETONE BODIES; MALE; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX;

EID: 80053908399     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-12-137     Document Type: Article

References (36)

1. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama 1997, 278(16):1349-1356. 10.1001/jama.278.16.1349, 9343467.
2. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nature reviews 2008, 9(10):768-778. 10.1038/nrn2494, 18802446.
3. de Leon MJ, Ferris SH, George AE, Christman DR, Fowler JS, Gentes C, Reisberg B, Gee B, Emmerich M, Yonekura Y, et al. Positron emission tomographic studies of aging and Alzheimer disease. AJNR Am J Neuroradiol 1983, 4(3):568-571.
4. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(1):284-289. 10.1073/pnas.2635903100, 314177, 14688411.
5. Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ. Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol 2007, 42(1-2):129-138. 10.1016/j.exger.2006.05.016, 16839732.
6. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005, 25(34):7709-7717. 10.1523/JNEUROSCI.2177-05.2005, 16120771.
7. Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. J Nucl Med 1996, 37(2):201-208.
8. Liang WS, Reiman EM, Valla J, Dunckley T, Beach TG, Grover A, Niedzielko TL, Schneider LE, Mastroeni D, Caselli R, et al. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(11):4441-4446. 10.1073/pnas.0709259105, 2393743, 18332434.
9. Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E, Tremblay S, Castellano A, Pifferi F, Bocti C, Paquet N, et al. Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition (Burbank, Los Angeles County, Calif 2011, 27(1):3-20.
10. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. Journal of neurochemistry 1977, 28(5):897-916. 10.1111/j.1471-4159.1977.tb10649.x, 864466.
11. Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF. Brain metabolism during fasting. The Journal of clinical investigation 1967, 46(10):1589-1595. 10.1172/JCI105650, 292907, 6061736.
12. Henderson ST. Ketone bodies as a therapeutic for Alzheimer's disease. Neurotherapeutics 2008, 5(3):470-480. 10.1016/j.nurt.2008.05.004, 18625458.
13. Prins ML. Cerebral metabolic adaptation and ketone metabolism after brain injury. J Cereb Blood Flow Metab 2008, 28(1):1-16. 10.1038/sj.jcbfm.9600543, 2857668, 17684514.
14. Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, Hyde K, Chapman D, Craft S. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiology of aging 2004, 25(3):311-314. 10.1016/S0197-4580(03)00087-3, 15123336.
15. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutrition & metabolism 2009, 6(1):31. 3191520, 22003431.
16. Roses AD, Sauders AM. Perspective on a pathogenesis and treatment of Alzheimer's disease. Alzheimer's and Dementia 2006, 2:59-70. 10.1016/j.jalz.2005.12.001, 3191869, 22003296.
17. Bach AC, Ingenbleek Y, Frey A. The usefulness of dietary medium-chain triglycerides in body weight control: fact or fancy?. Journal of lipid research 1996, 37(4):708-726.
18. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain pathology (Zurich, Switzerland) 2008, 18(2):240-252.
19. McNaull BB, Todd S, McGuinness B, Passmore AP. Inflammation and anti-inflammatory strategies for Alzheimer's disease--a mini-review. Gerontology 2010, 56(1):3-14. 10.1159/000237873, 19752507.
20. Shaftel SS, Griffin WS, O'Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. Journal of neuroinflammation 2008, 5:7. 10.1186/1742-2094-5-7, 2335091, 18302763.
21. Nalbantoglu J, Gilfix BM, Bertrand P, Robitaille Y, Gauthier S, Rosenblatt DS, Poirier J. Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. Annals of neurology 1994, 36(6):889-895. 10.1002/ana.410360614, 7998776.
22. Hasselbalch SG, Madsen PL, Hageman LP, Olsen KS, Justesen N, Holm S, Paulson OB. Changes in cerebral blood flow and carbohydrate metabolism during acute hyperketonemia. The American journal of physiology 1996, 270(5 Pt 1):E746-751.
23. Wang D, Pascual JM, Yang H, Engelstad K, Jhung S, Sun RP, De Vivo DC. Glut-1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Annals of neurology 2005, 57(1):111-118. 10.1002/ana.20331, 15622525.
24. Gu HF, Efendic S, Nordman S, Ostenson CG, Brismar K, Brookes AJ, Prince JA. Quantitative trait loci near the insulin-degrading enzyme (IDE) gene contribute to variation in plasma insulin levels. Diabetes 2004, 53(8):2137-2142. 10.2337/diabetes.53.8.2137, 15277398.
25. Pan JW, Rothman TL, Behar KL, Stein DT, Hetherington HP. Human brain beta-hydroxybutyrate and lactate increase in fasting-induced ketosis. J Cereb Blood Flow Metab 2000, 20(10):1502-1507.
26. Hall SK, Perregaux DG, Gabel CA, Woodworth T, Durham LK, Huizinga TW, Breedveld FC, Seymour AB. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis and rheumatism 2004, 50(6):1976-1983. 10.1002/art.20310, 15188375.
27. Neufeld HA, Pace JG, Kaminski MV, George DT, Jahrling PB, Wannemacher RW, Beisel WR. A probable endocrine basis for the depression of ketone bodies during infectious or inflammatory state in rats. Endocrinology 1980, 107(2):596-601. 10.1210/endo-107-2-596, 6993191.
28. Neufeld HA, Kaminski MV, Wannemacher RW. Effect of inflammatory and noninflammatory stress on ketone bodies and free fatty acids in rats. The American journal of clinical nutrition 1977, 30(8):1357-1358.
29. Thibault R, De Coppet P, Daly K, Bourreille A, Cuff M, Bonnet C, Mosnier JF, Galmiche JP, Shirazi-Beechey S, Segain JP. Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. Gastroenterology 2007, 133(6):1916-1927. 10.1053/j.gastro.2007.08.041, 18054563.
30. Thibault R, Blachier F, Darcy-Vrillon B, de Coppet P, Bourreille A, Segain JP. Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflammatory bowel diseases 2010, 16(4):684-695.
31. Marcondes S, Turko IV, Murad F. Nitration of succinyl-CoA:3-oxoacid CoA-transferase in rats after endotoxin administration. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(13):7146-7151. 10.1073/pnas.141222598, 34637, 11416199.
32. Ariza MJ, Sanchez-Chaparro MA, Baron FJ, Hornos AM, Calvo-Bonacho E, Rioja J, Valdivielso P, Gelpi JA, Gonzalez-Santos P. Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study. BMC medical genetics 2010, 11:66. 2877669, 20429872.
33. Craft S, Asthana S, Schellenberg G, Cherrier M, Baker LD, Newcomer J, Plymate S, Latendresse S, Petrova A, Raskind M, et al. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 1999, 70(2):146-152. 10.1159/000054469, 10461029.
34. Studzinski CM, Mackay WA, Beckett TL, Henderson ST, Murphy MP, Sullivan PG, Burnham WM. Induction of ketosis may improve mitochondrial function and decrease steady-state amyloid-beta precursor protein (APP) levels in the aged dog. Brain research 2008, 1226:209-217.
35. Taha AY, Henderson ST, Burnham WM. Dietary enrichment with medium chain triglycerides (AC-1203) elevates polyunsaturated fatty acids in the parietal cortex of aged dogs: implications for treating age-related cognitive decline. Neurochemical research 2009, 34(9):1619-1625. 10.1007/s11064-009-9952-5, 19301124.
36. Henderson ST. Ketone bodies as a therapeutic for Alzheimer's disease. Emerging Drugs and Targets for Alzheimer's Disease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism 2010, Martinez A.